| Title |
|
Prognostic Markers in Core-Binding Factor AML and Improved Survival with Multiple Consolidation Cycles of Intermediate/High-dose Cytarabine. |
|
|
| Publication Date |
|
| Author(s) |
|
| Subject |
|
| Type of document |
|
| OrcId |
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
| DOI |
|
| Abstract |
|
Core-binding factor acute myeloid leukaemia (CBF AML) defined by t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22) has a favourable prognosis, however 30-40% of patients still relapse after chemotherapy. We sought to evaluate risk factors for relapse in a de novo CBF AML cohort. A retrospective review of patients from 4 Australian tertiary centres from 2001-2012, comprising 40 t(8;21) and 30 inv(16) AMLs. Multivariate analysis identified age (p=0.032) and WCC>40 (p=0.025) as significant predictors for inferior OS and relapse respectively. Relapse risk was higher in the inv(16) group vs the t(8;21) group (57% vs 18%, HR 4.31, 95% CI: 1.78-10.42, p=0.001). Induction therapy had no bearing on OS or relapse free survival (RFS) however, consolidation treatment with >3 cycles of intermediate/high dose cytarabine improved OS (p=0.035) and relapse-free survival (RFS) (p=0.063). 5 patients demonstrated post-treatment stable q PCR positivity without relapse. (1)>3 consolidation cycles of intermediate/ high-dose cytarabine improves patient outcomes. (2)Age and inv(16) CBF AML subtype are predictors of inferior OS and RFS respectively. (3)Stable low-level MRD by qPCR does not predict relapse. (4)Similar OS in the inv(16) cohort compared to the t(8;21) cohort, despite a higher relapse rate, confirms salvageability of relapsed disease. This article is protected by copyright. All rights reserved. |
|
|
| Link |
|
| Citation |
|
European journal of haematology 2018; online first: 2 May |
|
|
| Jornal Title |
|
European journal of haematology |
|
|
